ORIC Pharmaceuticals ORIC Stock
ORIC Pharmaceuticals Price Chart
ORIC Pharmaceuticals ORIC Financial and Trading Overview
| ORIC Pharmaceuticals stock price | 7.84 USD |
| Previous Close | 8.45 USD |
| Open | 8.5 USD |
| Bid | 6.43 USD x 200 |
| Ask | 10.67 USD x 200 |
| Day's Range | 8.24 - 9.13 USD |
| 52 Week Range | 7.23 - 14.93 USD |
| Volume | 3.61M USD |
| Avg. Volume | 1.83M USD |
| Market Cap | 929.59M USD |
| Beta (5Y Monthly) | 1.105 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.39 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 20.36 USD |
ORIC Valuation Measures
| Enterprise Value | 599.52M USD |
| Trailing P/E | N/A |
| Forward P/E | -5.79041 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 2.2360559 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -4.031 |
Trading Information
ORIC Pharmaceuticals Stock Price History
| Beta (5Y Monthly) | 1.105 |
| 52-Week Change | -0.23% |
| S&P500 52-Week Change | 27.69% |
| 52 Week High | 14.93 USD |
| 52 Week Low | 7.23 USD |
| 50-Day Moving Average | 9.75 USD |
| 200-Day Moving Average | 10.83 USD |
ORIC Share Statistics
| Avg. Volume (3 month) | 1.83M USD |
| Avg. Daily Volume (10-Days) | 1.29M USD |
| Shares Outstanding | 103.52M |
| Float | 82.53M |
| Short Ratio | 15.51 |
| % Held by Insiders | 5.85% |
| % Held by Institutions | 113.77% |
| Shares Short | 21.94M |
| Short % of Float | 21.42% |
| Short % of Shares Outstanding | 21.20% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -27.57% |
| Return on Equity (ttm) | -42.56% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -148716992 USD |
| Net Income Avi to Common (ttm) | -135214000 USD |
| Diluted EPS (ttm) | -1.39 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 281.93M USD |
| Total Cash Per Share (mrq) | 2.72 USD |
| Total Debt (mrq) | 6.73M USD |
| Total Debt/Equity (mrq) | 1.62 USD |
| Current Ratio (mrq) | 16.332 |
| Book Value Per Share (mrq) | 4.016 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -110875000 USD |
| Levered Free Cash Flow (ttm) | -67968624 USD |
Profile of ORIC Pharmaceuticals
| Country | United States |
| State | CA |
| City | South San Francisco |
| Address | 240 E. Grand Ave |
| ZIP | 94080 |
| Phone | 650 388 5600 |
| Website | https://www.oricpharma.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 104 |
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and rinzimetostat formerly known as ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study. It has a clinical trial collaboration and supply agreement with Bayer to evaluate ORIC-944 in combination with Nubeqa AR inhibitor; and a clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC 944 in combination with Erleada AR inhibitor. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
Q&A For ORIC Pharmaceuticals Stock
What is a current ORIC stock price?
ORIC Pharmaceuticals ORIC stock price today per share is 7.84 USD.
How to purchase ORIC Pharmaceuticals stock?
You can buy ORIC shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for ORIC Pharmaceuticals?
The stock symbol or ticker of ORIC Pharmaceuticals is ORIC.
Which industry does the ORIC Pharmaceuticals company belong to?
The ORIC Pharmaceuticals industry is Biotechnology.
How many shares does ORIC Pharmaceuticals have in circulation?
The max supply of ORIC Pharmaceuticals shares is 103.52M.
What is ORIC Pharmaceuticals Price to Earnings Ratio (PE Ratio)?
ORIC Pharmaceuticals PE Ratio is now.
What was ORIC Pharmaceuticals earnings per share over the trailing 12 months (TTM)?
ORIC Pharmaceuticals EPS is -1.39 USD over the trailing 12 months.
Which sector does the ORIC Pharmaceuticals company belong to?
The ORIC Pharmaceuticals sector is Healthcare.
ORIC Pharmaceuticals ORIC included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 26853.98 USD — |
-0.89
|
8.32B USD — | 26769.16 USD — | 27130.88 USD — | — - | 8.32B USD — |
| US Tech Health Care IXHC | 1133.51 USD — |
+1.54
|
— — | 1113.35 USD — | 1133.95 USD — | — - | — — |
| Stlmt ID US Tech Biotechnology NBX | 3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
| US Tech Global Select Market Com NQGS | 13180.97 USD — |
-0.87
|
— — | 13139.79 USD — | 13316.81 USD — | — - | — — |
| US Tech Biotechnology NBI | 5807.22 USD — |
+1.87
|
— — | 5685.34 USD — | 5809.82 USD — | — - | — — |
- {{ link.label }} {{link}}